

ENABLE: A Phase 1 Study of ELVN-001, a Novel, Selective ATP-Competitive Inhibitor of BCR::ABL1, in Patients with Previously Treated CP-CML

Fadi G. Haddad¹, Dennis Dong Hwan Kim², Fabian Lang³; Michael Mauro⁴; Dong-Wook Kim⁵; Susan Saussele⁶; Philipp le Coutre⁷; Michael C. Heinrich⁸; Sarah Altmeyer⁹; Naranie Shanmuganathan¹⁰; Elvira Mora Castera¹¹; Raquel de Paz Arias¹²; Koji Sasaki¹; Franck E. Nicolini¹³; Valerie Coiteux¹⁴; Dragana Milojkovic¹⁵; Gabriel Etienne¹⁶; Nicole Blijlevens¹⁷; Yingsi Yang¹⁸; Qi Wang¹⁸; Brianna Hoffner¹⁸; M. Damiette Smit¹⁸; Andreas Hochhaus¹⁹

¹The University of Texas MD Anderson Cancer Center, Houston, Texas, USA ²Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada; ³Department of Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany; ⁴Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si, South Korea; ⁶Medizinische Fakultät Mannheim der Universität, Heidelberg, Germany; ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany; ⁸Knight Cancer Institute, Portland, OR, USA; ⁹Universitätsklinikum des Saarlandes, Homburg, Germany; ¹⁰Royal Adelaide Hospital, Adelaide, South Australia, Australia; ¹¹Hospital Universitario y Politecnico La Fe, Valencia, Spain; ¹²Hospital Universitario La Paz, Madrid, Spain; ¹³Centre Léon Bérard & INSERM U1052 CRCL, Lyon, France; ¹⁴Service des Maladies du Sang Hôpital Huriez - CHRU de Lille, Lille, France; ¹⁵Hammersmith Hospital, Imperial College NHS Trust, London, England; ¹⁶Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, France; ¹⁷Department of Hematology, Radboud University Medical Centre, Nijmegen, Netherlands; ¹⁸Enliven Therapeutics, Burlingame, CA, USA; ¹⁹Universitätsklinikum Jena, Jena, Germany

ELVN-001: A Highly Selective ATP-Competitive Inhibitor of BCR::ABL1



ELVN-001 was designed to address key unmet challenges in CML

Potency without Off-Target Toxicity¹

- ELVN-001 delivers **potent** inhibition of BCR::ABL1 with **high ABL1 selectivity**: >100-fold selectivity against >99% of 370 kinases; no inhibition of KIT, VEGFR2, PDGFR, or SRC


Resistance^{2,3}

- ELVN-001 showed activity against T315I and the emerging class of mutations associated with resistance to allosteric inhibition
- Not a P-gp or BCRP substrate or inhibitor

Administration Limitations^{4,5}

- Once daily administration of ELVN-001 with or without food
- Potential for concomitant administration with CYP3A4 substrates or inhibitors and proton pump inhibitors

BCR::ABL1



ELVN-001 has a unique P-loop folded-in binding mode

ATP, adenosine triphosphate; BCR::ABL1, breakpoint cluster region-Abelson leukemia virus 1; BCRP, breast cancer resistant protein; P-gp, P-glycoprotein


¹Lee H, et al. Int J Hematol. 2021; ²Hegedus, et al. Clin Transl Sci. 2022; ³Braun T, et al. Cancer Cell. 2020; ⁴Osorio S, et al. Ann Hematol. 2018; ⁵Cheng F, et al. Crit Rev Oncol Hematol. 2024

SOHO 2026: September 9-12, 2026; Houston, TX

ELVN-001: Differentiated by its Selective ABL1 Inhibition


ELVN-001

ABL1




Imatinib

Also inhibits:
KIT, CSFR-1, PDGFR




Dasatinib

Also inhibits:
SRC family, KIT,
PDGFR




Nilotinib

Also inhibits:
KIT, PDGFR, CSFR-1,
DDR-1, hERG channel




Bosutinib

Also inhibits:
SRC family



Ponatinib

Also inhibits:
KDR, FGFR, KIT, RET,
FLT3, PDGFR



ELVN-001 provides greater selectivity than available ATP inhibitors^a, with potential for better tolerability

^aEach of these active site TKIs was profiled at 30x its respective ABL1 IC₅₀ value against a panel of 377 protein kinases in biochemical assays with 100 mM ATP concentration in the screen (Reaction Biology) (Metz KS et al. Cell Systems. 2018).

ELVN-001: Phase 1 Trial Design and Status

Key Eligibility Criteria:

- Chronic phase CML
- Failed, intolerant to, or not a candidate for available therapies known to be active for treatment of their CML
- Typical or atypical transcripts

Primary Endpoints

- Incidence of DLTs, AEs, clinically significant laboratory and ECG abnormalities

Key Secondary Endpoints

- Molecular response by central qPCR
- PK parameters

Phase 1a Dose Escalation

10 mg–120 mg QD
60 mg–120 mg BID
N = up to ~80

✓ Complete

Phase 1b Dose Expansion (non-T315I)

60 mg QD
N = 20

80 mg QD
N = 20

120 mg QD
N = 21

✓ Complete

Optimal Biological Dose (OBD)
identified as 80 mg QD
Based on safety/tolerability, anti-CML activity, and PK/PD modeling

80 mg QD
N = 40

● Enrolling

Phase 1 is ongoing (NCT05304377). AE, adverse event; DLT, dose-limiting toxicity; ECG, electrocardiogram; BID, twice daily; OBD, optimal biological dose; CML, chronic myeloid leukemia; PD, pharmacodynamics; PK, pharmacokinetics; QD, once daily; qPCR, quantitative polymerase chain reaction.

Patient Demographics and Baseline Characteristics

Parameter	All Patients (N = 161 ^a)	80 mg QD (Phase 1b) (N = 49)
Median age in years (range)	59 (19–82)	57 (19–82)
Typical BCR::ABL1 transcript (e13a2/e14a2), n (%)	150 (93%)	47 (96%)
Baseline BCR::ABL1 transcript ^b ≤0.1%	26 (17%)	8 (17%)
>0.1% – 1%	37 (25%)	11 (23%)
>1% – 10%	28 (19%)	10 (21%)
>10%	50 (33%)	10 (21%)
Baseline BCR::ABL1 mutation (Sanger), n (%)	39 (24%)	5 (10%)
T315I mutation	12 (7%)	n/a
Mutations associated with resistance to allosteric inhibition	13 (8%)	2 (4%)
Other mutations	9 (6%)	3 (6%)

^a Includes 3 re-enrolled patients (158 individual patients)

Parameter	All Patients (N = 161 ^a)	80 mg QD (Phase 1b) (N = 49)
Median lines of prior TKI therapy, n (range)	4 (1–10)	3 (1–9)
Median number of prior unique TKIs, n (range)	3 (1–7)	3 (1–6)
1–2 prior, n (%)	46 (29%)	19 (39%)
3 prior, n (%)	39 (24%)	11 (22%)
4 prior, n (%)	37 (23%)	11 (22%)
≥ 5 prior, n (%)	37 (23%)	7 (14%)
Prior asciminib or ponatinib at any time, n (%)		
Asciminib ^b	100 (62%)	27 (55%)
Ponatinib	60 (37%)	13 (27%)
Reason for discontinuation of last TKI, n (%) ^c		
Lack of efficacy	99 (61%)	25 (51%)
Lack of tolerability	51 (32%)	20 (41%)

^b Most received asciminib in late line and the majority discontinued asciminib due to lack of efficacy

^c Unknown/other in 9 patients (all patients) and 3 patients (80 mg QD)

Majority of patients received ≥ 3 prior TKIs (70%) and prior ponatinib and/or asciminib (72%)

Patient Disposition: Majority of Patients Remain on Study

Disposition	All Patients (N = 161)	80 mg QD (Phase 1b) (N = 49)
Median duration of exposure, weeks (range)	35 (0.1–156)	16.1 (0.3–86.7)
Ongoing, n (%)	123 (76%)	40 (82%)
Discontinued, total n (%)	38 (24%)	9 (18%)
Lack of efficacy	21 (13%)	1 (2.0%)
Adverse event	10 (6.2%)	3 (6.1%)
Death	1 (0.6%)	1 (2.0%)
Other ^a	6 (3.7%)	4 (8.2%)

^a Protocol violation, investigator decision, and consent withdrawal

Overall, 146 person-years of exposure and 118 patients treated at doses $\geq$ 80 mg QD

At 80 mg QD in phase 1b:

- 82% of patients remain on study
- Current median duration of exposure of 16 weeks (cohort actively enrolling)
- Low rate of discontinuation due to adverse events

- No patients progressed to blast phase
- Death was due to post-operative complication (not related to ELVN-001)

ELVN-001 had Favorable Safety and Tolerability

- **Wide therapeutic window**
 - 80 mg BID determined to be MTD:
 - 2 patients with DLT at 120 mg BID (one Grade 3 hallucination in patient with history of hallucinations and one Grade 3 myalgia)
 - Low incidence of AOE^{*}:
 - 7 patients (4.4%) with any grade; 3 (1.9%) with Grade 3, all with CV disease/risk factors incl. prior nilotinib and/or ponatinib
- **Safety of 80 mg QD similar to overall safety; determination of optimal biological dose based on PK/PD modeling**

Most Common TEAEs (by Preferred Term), n (%)	All Patients (N = 158 Safety Analysis Set)		80 mg QD (N = 62 Safety Analysis Set)	
	Any	≥ Grade 3	Any	≥ Grade 3
Any TEAE	142 (90%)	53 (34%)	51 (82%)	15 (24%)
Hematologic TEAEs ≥ 5%				
Thrombocytopenia ^a	23 (15%)	10 (6.3%)	10 (16%)	4 (6.5%)
Neutropenia ^a	11 (7.0%)	10 (6.3%)	1 (1.6%)	0
Non-hematologic TEAEs ≥ 10%				
Lipase increased	35 (22%)	9 (5.7%) ^b	13 (21%)	3 (4.8%) ^b
Fatigue	28 (18%)	2 (1.3%) ^b	7 (11%)	1 (1.6%) ^b
Headache	24 (15%)	1 (0.6%) ^b	11 (18%)	1 (1.6%) ^b
Arthralgia	22 (14%)	2 (1.3%) ^b	10 (16%)	1 (1.6%) ^b
Myalgia	22 (14%)	1 (0.6%) ^b	7 (11%)	0
Nausea	19 (12%)	0	8 (13%)	0
Diarrhea	18 (11%)	0	6 (9.7%)	0
Amylase increased	16 (10%)	0	5 (8.1%)	0

^a Grouped terms: platelet count decreased/thrombocytopenia and neutrophil count decreased/neutropenia

^b Grade 3 only

Data cutoff: 10 Mar 2026.

TEAE, treatment-emergent adverse event. *AOEs (arterial occlusive events) identified by MedDRA. TEAE of hypertension, any grade, reported in 5.7% of patients, 1.9% Grade 3.


SOHO 2026: September 9-12, 2026; Houston, TX

Encouraging Anti-CML Activity in Phase 1b

Key Efficacy Milestones by Week 24 for Phase 1b

	Total QD (Phase 1b) (N = 90)	80 mg QD (Phase 1b) (N = 49)
Median exposure (weeks)	28.0 (0.3-86.7)	16.1 (0.3-86.7)
MMR ($BCR::ABL1 \leq 0.1\%$)		
Overall MMR	37/69 (54%)	17/28 (61%)
MMR achieved	21/53 (40%)	10/21 (48%)
MMR maintained	16/16 (100%)	7/7 (100%)
MR2 ($BCR::ABL1 \leq 1\%$)		
MR2 achieved	19/33 (58%)	9/13 (69%)
DMR ($BCR::ABL1 \leq 0.01\%$)		
DMR achieved	14/64 (22%)	8/27 (30%)

Cumulative Incidence of MMR in Patients Not in MMR at Baseline



^aPatients enrolled to phase 1a were allowed to increase the dose if certain criteria were met

Data cutoff: 10 Mar 2026.

DMR, deep molecular response; MMR, major molecular response; NOTE: Patients were included if they had baseline typical $BCR::ABL1$ transcript, and postbaseline assessment of $BCR::ABL1$ transcript at 24 weeks or achieved $MMR/\leq 1\%$ within 24 weeks or discontinued treatment before 24 weeks without achieving $MMR/\leq 1\%$. For patients with $MMR/\leq 1\%$ at baseline, only postbaseline assessments beyond 70 days were included in the analysis.

All Patients in Phase 1b had Improved or Stable MR Category

Change in *BCR::ABL1* Transcript in Patients Evaluable for MMR by Week 24 (N = 69)


		<i>BCR::ABL1</i> transcript (%) at baseline					
		≥MR4.5 ≤0.0032 (N = 4)	MR4 > 0.0032 to 0.01 (N = 1)	MR3 > 0.01 to 0.1 (N = 11)	> 0.1 to 1 (N = 21)	> 1 to 10 (N = 15)	> 10 (N = 17)
<i>BCR::ABL1</i> transcript (%) by Week 24	≥MR4.5 ≤0.0032	4	1	4	5	2	
	MR4 > 0.0032 to 0.01			1	1	1	
	MR3 > 0.01 to 0.1			6	6	4	2
	> 0.1 to 1				9	4	5
	> 1 to 10					4	3
	> 10						7

In subgroup with baseline transcript >10%:
59% (10/17) had improved MR category

Data cutoff: 10 Mar 2026.

NOTE: Evaluable patients had baseline typical *BCR::ABL1* transcript without T315I mutation and post-baseline assessment of *BCR::ABL1* transcript at 24 weeks or achieved MMR within 24 weeks or discontinued treatment before 24 weeks without achieving MMR. For patients with MMR at baseline, only post-baseline assessments beyond 70 days were included in the analysis.

Encouraging MMR Rates Across Lines of Therapy and After Asciminib Failure



*Maintained: 100% for all groups

Data cutoff: 10 Mar 2026.
NOTE: Analysis by number of prior TKIs done with prior *unique* TKIs. Evaluable patients had baseline typical BCR::ABL1 transcript without T315I mutation and post-baseline assessment of BCR::ABL1 transcript at 24 weeks or achieved MMR within 24 weeks or discontinued treatment before 24 weeks without achieving MMR. For patients with MMR at baseline, only post-baseline assessments beyond 70 days were included in the analysis.

Conclusions

ELVN-001 showed favorable safety and tolerability with longer follow-up

- Low rate of discontinuations due to TEAEs
- The safety profile is consistent with ELVN-001's selectivity for ABL1
- No evidence of increased cardiovascular toxicity to date

The Optimal Biological Dose was determined to be 80 mg QD based on safety, efficacy, PK/PD

Encouraging anti-CML activity continued to be observed

- At the OBD of 80 mg QD in Phase 1b: 61% overall MMR with 48% achieving MMR by Week 24
- MR stable or improved in all patients enrolled in Phase 1b
- Encouraging MMR rates even in heavily pretreated patients and after asciminib failure

Phase 3 ENABLE-2 pivotal trial is expected to initiate in the second half of 2026

ELVN-001, an ATP-competitive BCR::ABL1 TKI with high selectivity for ABL1, demonstrated favorable safety and efficacy profile at biologically active doses

Thank you

**to all investigators and site staff, and to the patients and their
families for their participation in the study**

This study was funded by Enliven Therapeutics, Inc.